Forecasting the Growth of Braftovi + Erbitux ± Mektovi in the Cancer Treatment Market by 2032
Overview of Braftovi + Erbitux ± Mektovi Combination The combination therapy involving Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become a vital treatment strategy for certain cancers, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted approach utilizes BRAF and